LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is expected to release its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.91) per share and revenue of $3.0880 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ opened at $11.74 on Tuesday. LENZ Therapeutics has a 52 week low of $11.21 and a 52 week high of $50.40. The firm’s 50-day simple moving average is $14.91 and its 200 day simple moving average is $25.72. The firm has a market cap of $367.34 million, a price-to-earnings ratio of -5.56 and a beta of 0.52.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Zacks Research lowered LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a research report on Tuesday, March 10th. Finally, Wall Street Zen raised LENZ Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.40.

Institutional Trading of LENZ Therapeutics

Hedge funds have recently modified their holdings of the business. Quarry LP purchased a new stake in shares of LENZ Therapeutics during the third quarter valued at approximately $27,000. State of Wyoming purchased a new position in shares of LENZ Therapeutics during the 4th quarter valued at $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of LENZ Therapeutics during the fourth quarter valued at approximately $32,000. Osaic Holdings Inc. grew its holdings in LENZ Therapeutics by 2,146.2% during the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after buying an additional 1,116 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in LENZ Therapeutics by 51.4% during the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after purchasing an additional 477 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.